recurrent respiratory papillomatosis

Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage.

By Frank Vinluan

BioPharma, Pharma

Jet trail creating dollar sign in blue sky with clouds startup capital

First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen?

Precigen’s Papzimeos is the first FDA-approved drug for the rare disease recurrent respiratory papillomatosis, or RRP. While this immunotherapy carries blockbuster expectations, Precigen’s financial reports indicate budgetary challenges.

By Frank Vinluan